Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186576 · ClinicalTrials.gov registry record · NA
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00186576: Completed NA study, sponsored by Stanford University.
NCT00186576 is a NA study that has completed, run by Stanford University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186576, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Interventions
- PROCEDURE nonmyeloablative allogeneic hematopoietic cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-12 |
| Est. Completion | 2010-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186576
The ClinicalTrials.gov registry entry for NCT00186576 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nonmyeloablative allogeneic hematopoietic cell transplant is the first listed.
NCT00186576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186576 about?
NCT00186576 is a clinical study titled "Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders". To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
What is the current status of trial NCT00186576?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2001-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00186576?
The interventions under investigation include: nonmyeloablative allogeneic hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186576?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.